Drug
Relmapirazin clinical trials
Also written MB-102.
- studies test it
- 8
- open now
- 1
- in phase 3
- 3
- first study started
- 2016
Keep track of what changes. Save the relmapirazin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 2
- Phase 2
- 2
- Phase 3
- 3
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 1
MediBeacon (5) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (1) · Aaron Cook (1) · Mustang Bio (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses relmapirazin is read from its arms, and is right about nine times in ten.
Testing it · 8
- Fluorescent Probe for Assessment of Renal EliminationRecruitingPhase 4Aaron CookNCT07643467Written as Relmapirazin
- Evaluation of Lumitrace for Visualizing Ureters During Abdominopelvic SurgeriesActive, not recruitingPhase 1MediBeaconNCT07080008Written as Lumitrace
- Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive RingCompletedPhase 3MediBeaconNCT05777174Written as MB-102
- Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.TerminatedPhase 1/2Mustang BioNCT04109482Written as MB-102
- Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised SubjectsCompletedPhase 3MediBeaconNCT05425719Written as MB-102
- A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese ParticipantsCompletedPhase 3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT05943977Written as MB-102 DMID
- Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color TypesCompletedPhase 2MediBeaconNCT02772276Written as MB-102-- single dose of 4 µmol/kg
- Oral Administration of MB-102 Versus Dual Sugar Testing for Gut PermeabilityCompletedEarly Phase 1MediBeaconNCT03962998Written as MB-102
Codes
What other systems call relmapirazin · ClinicalTrials.gg INT001265
- MeSH (NLM) C000657342relmapirazinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Q3UQB8PQ6HRELMAPIRAZINConfirmed FDA, NLM, Wikidata
- Wikidata Q123914020relmapirazinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152179RelmapirazinOne source FDA
- DrugBank DB19130One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000657342 | relmapirazin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Q3UQB8PQ6H | RELMAPIRAZIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123914020 | relmapirazin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152179 | Relmapirazin | One source FDA |
| DrugBank | DB19130 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.